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Abstract In this paper we recapitulate the history of the conceptual en-
twinement of biomedicine and translation and argue that a translational im-
perative has come to dominate public and institutional perceptions of bio-
medical research that is still peripheral to the practices that order the fields 
unified under the term biomedicine. We show this by first delineating a 
brief history of the conceptual developments in the sociology of science 
and technology in particular in relation to translation and the complex 
multi-agent social interactions contributing to the structure of this field. 
We then report the findings from our studies of translational spaces and 
how the actors in them conceive of the imperatives. The push toward 
translational research from funding and science policy institutions seems, 
however, at least in the field of cell therapy research, not to have altered 
greatly the established practices of validation and merit that organise the 
disciplinary complexes that form cell therapy biomedical research today. 
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1. Introduction 
 
We were invited to contribute a discussion of the concept of transla-
tional research and its emergence in biomedicine on the basis of our work 
on this topic. The history of the intersection of biomedicine and transla-
tional research is complicated, and therefore we discuss in this article the 
changing relationship between both, how they influence and grow to-
gether in what is a current translational imperative in which biological 
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and medical research give direction and set restrictions for one another. 
We use examples from cell therapy research, an area we conducted ex-
tensive empirical research on, assuming that whilst the configuration of 
biomedicine through translation may play out differently in detail in dif-
ferent fields of biomedicine, the degree and influence of the translational 
imperative has similar structural effects. 
 
 
1. Concepts of Biomedicine and Translational Research 
 
That medicine relates to biology is a trivial notion. That increasingly 
medical diagnosis has come to rely on biological/tissue tests, and that 
therapies intervene into biochemically well-defined physiological or 
metabolic processes, is a product of the 20th century. In this context the 
emergence of the concept of biomedicine has occurred. Biomedicine has 
changed medicine and constitutes a whole set of new practices and locali-
ties of research, including multidisciplinary laboratories, new journals and 
the grammar of research ethics and clinical trials. Viviane Quirke and 
Jean-Paul Gaudillière date the rise of biomedicine to after the Second 
Word War and characterize it as a “step change in the scale of investment 
in research, a new role for the state as scientific entrepreneur, an increas-
ingly fundamental level of investigation in biology and medicine, and a 
closer relationship between the laboratory and the clinic”, accompanied 
by the idea of “the therapeutic miracle” and the “search for magic bullets 
against tuberculosis, cancer, and cardiovascular disease” (Quirke and 
Gaudillière 2008: 442-3). Cell therapy research developed in this period 
as studies into the effects of nuclear radiation on the body and how de-
stroyed cell systems could be repaired. The stem cell in the bone marrow 
and its regenerative function for the blood system, and with it the leu-
kaemia patient, were determined as biomedical cell therapy research 
(Kraft 2009). 
 
 
1.1 The Translational Imperative 
 
Translation between the laboratory and the clinic may therefore seem 
to be at the core of the activity we call biomedicine. In its Funding guide 
the UK’s largest medical research funder, the Wellcome Trust, explains 
that, ‘Translational research helps turn early-stage innovations into new 
health products, advancing the innovation to the point where it becomes 
attractive for further development by the medical industry or healthcare 
agencies’1. This present-day definition suggests a one-directional flow of 
information, from the laboratory into general medical care, identifying !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 http://www.wellcome.ac.uk/funding/Innovations/wtd027704.htm 
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the envisioned gaps between the different stages of such innovation. The 
imperative, therefore, of what funding bodies and science policy manag-
ers have introduced as translational research lies on the concept of ‘pull-
ing through’; the problem is how to effectively turn new biological knowl-
edge into widely used medical treatments. The 2014 overview for the UK 
NIHR Biomedical Research Centres (BRC) stresses that all projects and 
project leaders must have a track record ‘in translating advances in basic 
biomedical research into clinical research, and pulling through basic bio-
medical research findings into benefits for patients, the public and the 
NHS’.2 
 
 
1.2 Biomedicine and Translation in Sociology 
 
The one-directional model stressed in the above notions of translation 
is simplistic compared to the ways in which the sociology of science and 
technology has been using the concept of translation since the 1960s. The 
scientists’ use of the metaphor translation for flows of knowledge and in-
formation across disciplines and their peculiar languages and practices 
was followed by the emergence of the sociology of translation. A name 
commonly attributed to Bruno Latour (1979), Michel Callon (1986) and 
others who worked in this field in the 1980s. Translation is a key concept 
in actor-network theory. Applied to the field of biomedicine it presents 
its main actors as attempting to create a central network of interactions 
that each actor has an interest in building and defending.  
The first is that of the reduction of the big world (the macro-
cosm) to the small world (the microcosm) of the laboratory. The 
second stage is that of the formation and setting to work of a re-
stricted research group that, relying on a strong concentration of in-
struments and abilities, devises and explores simplified objects.  The 
third stage is that of the always perilous return to the big world: ... 
(Callon et al. 2009: 48). 
This description points out that the flow of information and what is 
needed to achieve biomedical innovation is not from the bench to the 
bedside but a more complex interweaving of stages in which complexity 
is reduced and then reintroduced again. The emphasis is on interactive 
practices that produce translation as a reconfiguration of the macrocosm 
(ibid: 68). 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
2 http://www.nihr.ac.uk/files/pdfs/Briefing%20documents/4.2%20Biomedical%20Research%20Centres.pdf)  
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1.3 Science as Social Practice 
 
This focus on the performance of science also dates back to the 1960s 
when the knoweldge practices of science became a study object for soci-
ologists and, as Sheila Jasanoff recapitulates, sociologists began to “carry 
out science on science” (Jasanoff 1994: 6), a turn of attention aimed at ra-
tional policy decisions on science and technology innovation in the fu-
ture. Proponents of the Sociology of Scientific Knowledge (SSK) studied 
science as a social practice and consequently scientific knowledge as a so-
cial product (Barnes 1974 and 1977; Bloor 1976, Collins 1985; Shapin 
1982). In policy contexts this was taken up as a new imperative to under-
stand the developments in the sciences in their relationship to technology 
and economic growth and, above all, how “to get returns on the money 
we spend on science” (op. cit.: 6).  
SSK and its precursors, especially Ludwik Fleck (1979[1935]) and 
Thomas Kuhn (1970[1962]), began to understand science as the product 
of social processes and negotiations, which mediate scientists’ accounts of 
the natural world, raising fundamental questions about taken-for-granted 
divisions between “social versus cognitive, or natural, factors” (Shapin 
1995: 289). The ‘truth’ or ‘falsity’ of scientific claims derives from the in-
terpretations, actions and practices of scientists rather than residing in na-
ture as a separate world of facts that exists objectively for the scientists, 
independent of the methods and practices they employ to study it. Un-
derstanding science as a social practice includes not only studying its 
methods but also its social structures and the vested interests and social 
objectives that operate on and within the activity of making scientific 
knowledge.  
This perspective presents translation as a process in which the knowl-
edge practices of different fields in the macro-and-microcosms in bio-
medicine cooperate with social practices that influence the epistemic and 
internal stratification processes in complex webs of interactions. Scien-
tists and clinicians balance many and often conflicting expectations of 
what counts as achievement as set out by funding organisations, the scien-
tific community, publics, patients, industries and policy makers. The art 
of translation is to balance these expectations across disciplines and turn 
them into individual and institutional successes and desirable medical in-
novations. Biomedicine and translation thus is multi-layered, an inter-
weaving of interests and activities. From 2000s onward, the concept was 
further expanded in sociological studies on cell therapy research to dif-
ferent concepts of intersecting social spheres.  
 
 
2. Cell Therapy Research: New Understandings of Translation  
 
From its beginnings in bone marrow repair, research on cell therapies 
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has taken several forms over the past decades, diversifying into many ex-
pert areas. Thus the term cell therapy research now ties together a range 
of types of specialist expertise in both biology and medicine, strongly in-
fluenced by ethical and political factors (Hauskeller 2004). Paul Martin, 
Nik Brown and Alison Kraft (2008) chart the development of haema-
topoietic stem cell research over a fifty-year period and describe the rela-
tionship between basic science and clinical research communities as a 
two-way flow of knowledge in which clinical innovation has played a key 
role. They emphasize the communities of promise that form around 
emerging cell therapies and that national governments incentivize the ex-
ploitation of basic research and the creation of new policies and institu-
tions to ensure that scientific findings can be applied in the clinic.  
The large body of social science work on the external societal influ-
ences on cell therapy research from the past 15 years is accompanied by a 
number of studies on the translational processes within scientific com-
munities. For example, Steven Wainwright, Clare Williams, Mike Mi-
chael, Bobbie Farsides and Alan Cribb describe a distinction between the 
“warp of discourses which enact the improbability of collaborations be-
tween ‘bench’ and ‘bedside’, and the weft of other discursive strategies 
which enact the possibility of collaboration between the lab and the 
clinic” (2006: 2062). Steven Wainwright and Clare Williams (2008:165) 
draw on Livingstone’s metaphor of geographies of science, which he de-
scribed as “sites of speech and locations of locution” (2003:23) to explore 
the spatial shaping of science and the scientific shaping of conceptual, so-
cial and political spaces.  
 
 
2.1.  Platforms and Trading Zones 
 
The metaphor of the platform is moved from being applied to bio-
medicine to being used to characterize processes of translation. Peter 
Keating and Alberto Cambrosio describe biomedicine as a  ‘hybrid-
practice’ and their notion of the biomedical platform draws together 
panoply of diverse actors from technicians, physicians, and researchers, 
policy makers and regulators, with material objects (Keating and Cam-
brosio 2003). They argue that in the 1990s biomedicine itself had become 
an independent actor in cancer research, alongside basic and clinical re-
search (Cambrosio et al. 2006).  Joelle M. Abi-Rached, Nikolas Rose and 
Andrei Mogoutov re-configure the translational platform as an array of 
heterogeneous actors including technologies, practices and techniques 
and enabling multiple transactions between the clinic, the laboratory and 
society. They stress that the products of translational research, be they 
specific applications (drugs, neurodevices, etc.) or practical guidelines 
(systematic reviews, meta-analyses etc.) allow a change in both clinical 
practice and population behaviour, as identified by Steven Woolf (2008).  
In the context of their study on the new brain sciences, Abi-Rached et al. 
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distinguish areas of research that act as vectors between the laboratory, 
the clinic and society and argue that each specialized community is cen-
tred around its own journals, institutes and organizations. These are con-
nected in trading zones, a notion they develop following Peter Galison 
(1997), to capture not merely zones of passive exchange and flow of in-
formation, but   
“Zones which facilitate the active transactions and transmutations of 
diverse devices, practices, techniques, and perhaps above all styles of 
thought. They are platforms which allow the emergence of new disci-
plines and discursive practices and along with them a reorganization of 
their objects of study”. (Abi-Rached et al. 2010: 13)   
This notion of trading zones where translational activity is enacted is 
helpful to identify agency. However, engagement in the translational trad-
ing zone is not always deliberate, but affected by targeted policy deci-
sions. Whether we prefer the image of interconnected platforms or of the 
webs woven through multiple centres of agency, a social and political im-
perative to be translational acts upon biomedicine as shown across the 
range of social science studies. To illustrate this we provide a brief sum-
mary of findings from empirical research concerning the scientists’ view 
of, and practical engagement with, this imperative. 
 
 
2.2. The Utility Imperative in the Translational Space of Cell 
Therapy Research  
 
Between 2006 and 2011 the authors carried out ethnographic studies 
on stem cell research for the heart in laboratories, clinical environments 
and at networking events. Analysis drew on observation and semi-
structured interviews with laboratory scientists, clinicians and focussed 
on the regulatory, disciplinary and ethical tensions that shape the ‘transla-
tional space’ (Harrington 2011). In addition, we studied from its incep-
tion in 2004 the British Cardiovascular Collaborative for Stem Cell Repair 
of the Heart (Collaborative), a clinician-led multi-disciplinary group of 
top UK biomedical researchers who aimed at developing stem cell treat-
ments together instead of competitively in order to achieve fast clinical 
implementation. One of the aims of our research was to explore the moti-
vations and attitudes of the stakeholders working in this field. The data 
on practices, networks of interactions and interdisciplinary exchanges 
show that differently positioned participants in the field employed differ-
ent strategies to negotiate the translational imperative. The quotes below 
exemplify opposite views on translational research. And what we call the 
translational imperative. First a molecular biologist working in a labora-
tory funded for translational research: 
So I have to play the game, I have to play the rules of the game be-
cause in the end what I want is to be funded and to be in a lab working 
and doing research. [...] There are many things you can do with the cells I 
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work on. They are not necessarily going to translate into something use-
ful, but you can do the research and that research will be useful anyway. 
It may not be translated, but the point is, in a paper when I send my pro-
ject to the funders, it’s like, yeah, stem cells, a disease, a cure!  So… it’s 
more about, [pause] giving the people what they want to read, even if in-
side you know it’s not necessarily achievable, or it’s not your first priority, 
but again you have to combine all these things, basic research with trans-
lational research and get the money.  
The scientist states that conforming to the translational imperative is 
necessary in order to get funded.  Translational research is performed as 
an adjunct to the biological inquiry. The opposite perspective is pre-
sented by a clinical–scientist who states that biological research should be 
driven by medical needs and requirements, describing the purpose of the 
Collaborative and the view of the multidisciplinary group that met several 
times a year over a period of 7 years, as: 
All agreed that clinical researchers had first to define which problems 
they would attempt to treat with transplanted cells (e.g. heart failure, di-
lated cardiomyopathy, or myocardial infarction) and by what route (e.g. 
intravenous, percutaneous, or surgical). Then the groups working on 
animal models would adapt their models to that clinical need […] The 
group working on cells and gene transfer to cells would define the best 
cells to transplant, or the best way of stimulating endogenous cells to ac-
tivity.  
The clinicians participated in the Collaborative in order to find new 
methods to change the function of the ailing heart and expected the sci-
entists to provide them with the biological knowledge and cells to aid that 
goal without necessarily fully understanding the mechanisms by which 
the cells regenerate heart tissue. The clinical focus is on whether proce-
dures are safe3 and in the long term prove to be efficacious4. Innovation 
pathways for new cell therapies from the laboratory into the clinic have 
been promoted and pre-planned by both funding organisations such as 
the Wellcome Trust and regulatory institutions such as the UK Human 
Tissue Authority5 and the scientific interest currently focuses on new 
ways of creating cells with regenerative potential. Some of the clinicians 
involved in the Collaborative have formed a significant European Net-
work that won funding in 2011 for a large clinical trial with established 
stem cells, which they perceive as the ultimate test. The Collaborative as a !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
3 The Clinical Trials observed in this research were Phase 1 that is designed to ‘assess safety’ although often the 
conversations between clinicians were centred on ‘efficacy’. This dilemma raises questions concerning the ‘focus’ of a 
clinical trial and the ethics surrounding this position. 
4 When discussing this divide between the scientist and the practicing clinician reference was made to ‘Aspirin’ 
[acetylsalicylic acid (ASA)] and the fact that it’s functioning mechanisms have only relatively recently been discovered 
although it has been in use since 1500BC when an infusion of dried myrtle leaves (which contain salicylic acid) was used to 
relieve back pain and since 1899 under the trade name ‘Aspirin’. 
5 http://www.hta.gov.uk/_db/_documents/Role_of_regulators_in_regenerative_medicine.pdf 
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group however ceased meeting in 2012. This may be interpreted as a case 
in which the tensions between biological and medical research could not 
be resolved and the translational imperative failed to pull through the 
new treatments originally envisaged.  
The heteronomy of success indicators in the different fields of bio-
medicine seems still stronger than the commitment to translation, which 
is not directly one of them. Scientists and clinicians need to publish pa-
pers in top journals and the criteria which the translational imperative 
aims to introduce and add to the success stories of a particular biological 
or medical laboratory’s achievements, are not aligned with the internal 
workings of the sciences that contribute to biomedicine. The platforms 
are not aligned and thus the difference between publicly accountable re-
search and research excellence still overshadow compliance with this im-
perative of social and commercial utility.  
This case of stem cell research for the heart offers a valuation of the 
imperative for translational research that so far has not been very success-
ful. Research in other fields within biomedicine is likely to show equal 
levels of complexity, in which the justifications, initiatives, rhetoric, fund-
ing support, and other strategic mechanisms of facilitating translation 
may more successfully create the normative basis for science that trans-
lates into improved health.  
 
 
Conclusion  
 
Biomedicine and translational research as concepts have different his-
torical origins, yet, the necessity for multidirectional and multi-actor en-
gagement is inherent in both. Sociology has been analysing and reflecting 
on the social practices which shape the developments of translation and 
its penetration of more and more areas of biology and medicine which 
draws in a growing number of social sectors and agents. That research has 
to be oriented toward therapeutic application to deserve public funding 
and be of societal value is an imperative that contradicts and challenges to 
the point of denial the complexity of successful interactions and transfers 
between multiple agencies. Biomedicine is pregnant with translation. Im-
plied in the use of the metaphor of translation is that exchanges are trans-
formations in which the meaning, however well captured, shifts slightly 
between original text – be it the clinical or the laboratory’s – and the new 
text. The narrow reins with which regulators try to predetermine with 
simplistic notions of translation and to-do lists the outcome of the science 
yet to be conducted and how its results ought to be implemented negate 
the potential that lies in biomedicine as an evolving project for many kinds 
of clinical innovations and understandings of biology.  
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